Concord Biotech gets FDA-approval for Tofacitinib tablets

Concord Biotech gets FDA-approval for Tofacitinib tablets — Concord Biotech has received abbreviated new drug application (ANDA) approval from the US FDA for Tofacitinib Tablets, 5 mg and 10 mg, paving the way for market entry. The drug is a generic version of Xeljanz, used to treat rheumatoid arthritis and other inflammatory conditions. This approval expands Concord Biotech’s presence in the US generics market.
📊 STOCKS: CONCORDBIO | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDAApproval